CBD, for example, acts on various receptors as well as enzymes, transporters, and ion channels.[3] Furthermore, the CBD‐derivative CIAC001, which showed improved anti‐neuroinflammatory properties, was found to act on pyruvate kinase M2 (PKM2) as analyzed by affinity‐based protein profiling (AfBPP).[4] Both phytocannabinoids, THC and CBD, show great potential in the treatment of Alzheimer's disease (AD).[5] But especially since THC shows strong activity on CB1R and CB2R, its potential clinical application is limited due to its psychoactive side effects. This evidence concerns the gene CNR1 and Alzheimer disease.